COVID-19 pandemic and the risk of infection in multiple sclerosis patients on disease modifying therapies: “what the bleep do we know?”

COVID-19 pandemic and the risk of infection in multiple sclerosis patients on disease modifying therapies: “what the bleep do we know?”

Kevin Murphy, Salman Mansoor, Siobhán Kelly, Aine Waters, Nauman Saleem Siddiqui

Abstract The novel coronavirus which emerged in Wuhan province of China has taken world by surprise. Since been diagnosed in December 2019, it has been termed a “Pandemic” and there is a growing concern in physicians across the globe. As new evidence is emerging, there are various preventative strategies which are being deployed. Multiple sclerosis patients who are on disease modifying therapies (DMTs) might be at a higher risk of acquiring or a poorer outcome due to their immune status. This review looks at the available evidence in managing this global crisis.

2020

Multiple Sclerosis, coronavirus, disease modifying therapies, COVID-19

DOI: 10.1186/s41983-020-00177-0

The Egyptian Journal of Neurology, Psychiatry and Neurosurgery

SpringerOpen

Neurosciences. Biological psychiatry. Neuropsychiatry